World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
38421
World Ranking
11149
National Ranking
448

Daniel Gaudet publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Daniel Gaudet sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 509 publications — 59th percentile

59% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Daniel Gaudet D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel Gaudet sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 92 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Daniel Gaudet is affiliated with the University of Montreal in Canada and has contributed extensively to research in medicine and biochemistry, genetics, and molecular biology. Their work spans various subfields including surgery, cardiology and cardiovascular medicine, endocrinology, diabetes and metabolism, cancer research, and molecular biology.

The scientist's research primarily focuses on lipid metabolism and disorders, with significant attention to lipoproteins and cardiovascular health. Other notable topics in their body of work include the interrelation of cancer, lipids, and metabolism; diabetes, cardiovascular risks, and lipoproteins; hyperglycemia and glycemic control in critically ill and hospitalized patients; liver disease diagnosis and treatment; and pharmaceutical economics and policy.

Daniel Gaudet has frequently published in several key medical journals, including:

  • Atherosclerosis
  • Journal of Clinical Lipidology
  • Circulation
  • New England Journal of Medicine
  • Journal of the American College of Cardiology

Collaborations are a notable part of Gaudet's academic career. Frequent co-authors include Diane Brisson, Robert A. Hegele, Christie M. Ballantyne, Frederick J. Raal, and Robert S. Rosenson, reflecting interdisciplinary cooperation among researchers in cardiovascular and metabolic disease.

Noteworthy recent publications associated with Daniel Gaudet include:

  • Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society, 2021, European Heart Journal
  • Evinacumab for Homozygous Familial Hypercholesterolemia, 2020, New England Journal of Medicine
  • Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease, 2022, New England Journal of Medicine
  • Evinacumab in Patients with Refractory Hypercholesterolemia, 2020, New England Journal of Medicine
  • Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, 2021, The Lancet Respiratory Medicine

Best Publications

  • The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes.

    David Altshuler;Joel N. Hirschhorn;Joel N. Hirschhorn;Joel N. Hirschhorn;Mia Klannemark;Cecilia M. Lindgren;Cecilia M. Lindgren

  • Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia

    John J.P. Kastelein;Fatima Akdim;Erik S.G. Stroes;Aeilko H. Zwinderman

  • Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    Adrian F Hernandez;Jennifer B Green;Salim Janmohamed;Ralph B D'Agostino

  • Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?

    Isabelle Lemieux;Agnès Pascot;Charles Couillard;Benoı̂t Lamarche

  • Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

    Frederick J Raal;Raul D Santos;Dirk J Blom;A David Marais

  • Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease.

    John D. Rioux;Mark J. Daly;Mark S. Silverberg;Kerstin Lindblad

  • PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2) : a randomised, double-blind, placebo-controlled trial

    Frederick J Raal;Evan A Stein;Robert Dufour;Traci Turner

  • Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

    Evan A Stein;Dan Gipe;Jean Bergeron;Daniel Gaudet

  • Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

    Marina Cuchel;Emma A. Meagher;Hendrik Du Toit Theron;Dirk J. Blom;Dirk J. Blom

  • Common variants in the NLRP3 region contribute to Crohn's disease susceptibility

    Alexandra-Chloé Villani;Mathieu Lemire;Geneviève Fortin;Edouard Louis

  • Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.

    Claude Gagné;Daniel Gaudet;Eric Bruckert

  • Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

    Daniel Gaudet;Veronica J. Alexander;Brenda F. Baker;Diane Brisson

  • Evinacumab for Homozygous Familial Hypercholesterolemia

    Frederick J. Raal;Robert S. Rosenson;Laurens F. Reeskamp;G. Kees Hovingh

  • Targeting APOC3 in the Familial Chylomicronemia Syndrome

    Daniel Gaudet;Diane Brisson;Karine Tremblay;Veronica J. Alexander

  • Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society

    Henry N Ginsberg;Chris J Packard;M John Chapman;Jan Borén

  • Volanesorsen and triglyceride levels in familial chylomicronemia syndrome

    Joseph L Witztum;Daniel Gaudet;Steven D Freedman;Veronica J Alexander

  • Efficacy and long term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open label trial

    D Gaudet;J Méthot;S Déry;D Brisson

  • Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.

    Ulrich Laufs;Maciej Banach;G. B. John Mancini;Daniel Gaudet

  • Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia Results of a Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety as Add-On Therapy in Patients With Coronary Artery Disease

    Evan A. Stein;Robert Dufour;Claude Gagne;Daniel Gaudet

  • Haplotype Structure and Genotype-Phenotype Correlations of the Sulfonylurea Receptor and the Islet ATP-Sensitive Potassium Channel Gene Region

    Jose C. Florez;Noël Burtt;Paul I.W. de Bakker;Peter Almgren

Frequent Co-Authors

Tomáš Paus
Tomáš Paus University of Toronto
Thomas J. Hudson
Thomas J. Hudson Ontario Institute for Cancer Research
Jean-Pierre Després
Jean-Pierre Després Université Laval
Michal Abrahamowicz
Michal Abrahamowicz McGill University
Gabriel Leonard
Gabriel Leonard Montreal Neurological Institute and Hospital
Robert A. Hegele
Robert A. Hegele University of Western Ontario
Erik S.G. Stroes
Erik S.G. Stroes University of Amsterdam
Pavel Hamet
Pavel Hamet University of Montreal
John J.P. Kastelein
John J.P. Kastelein University of Amsterdam
Joel N. Hirschhorn
Joel N. Hirschhorn Boston Children's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees can open alternative career pathways in the health sector. For students who want to work in healthcare but don't wish to become physicians, nursing is a popular option. Many programs now cater to diverse backgrounds. For example, online direct entry MSN programs for non-nurses provide a fast track for individuals holding a non-nursing bachelor’s degree to transition into advanced nursing roles.

Admission standards also vary. Some schools offer direct entry nursing programs with less competitive requirements, making them more accessible for applicants. Additionally, those interested in supporting healthcare operations rather than providing hands-on care can consider studying at one of the best medical billing and coding schools online, which often offer financial aid.

For applicants concerned about admission exams, there are even nursing school that does not require teas test, simplifying the process further. These diverse online routes provide flexible, achievable alternatives for building a healthcare career in the USA.

Best Scientists Citing Daniel Gaudet

Trending Scientists